secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001326732-26-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M
--------------------------------------------------------------------------------

- Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.
- Cash $610.8M at Dec 31, 2025; expects $400-430M at end 2026, funding operations through 2028.
- XmAb819 (ENPP3 x CD3) dose expansion open in CRC, NSCLC, pRCC; plan to present data 2H26 for recommended Ph3 dose, pivotal start 2027.
- Xtend U.S. patent to Dec 2028; expects $100-120M aggregate royalty above OMERS cap from Ultomiris sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/0001326732-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/xncr-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001326732-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer